October 13, 2026 – Broward Health Medical Center has introduced bispecific T-cell engager (BiTE) therapy, an innovative immunotherapy that harnesses the body’s immune system to target and destroy cancer cells. The FDA-approved therapy is used to treat acute lymphoblastic leukemia (ALL), lymphoma, multiple myeloma, lung cancer and melanoma.
The first patient treated at Broward Health Medical Center on Oct. 12 received BiTE therapy for a specific type of lung cancer. Additional patients, including those with multiple myeloma, are expected to receive the therapy as appropriate.
“BiTE therapy represents an important advancement in cancer care because it brings the patient’s own immune system directly to the cancer cell,” said Dr. Blanc, M.D., medical director of hematology-oncology at Broward Health Medical Center. “By connecting T cells with specific targets on cancer cells, this therapy gives us another highly targeted treatment option for patients who may benefit from it.”…